Genes encoding tumor-specific antigens are expressed in human myeloma cells

Blood

Volumn 94, Issue 4, 1999, Pages 1156-1164

  Van Baren, Nicolas ^a   Brasseur, Francis ^b   Godelaine, Danièle ^b   Hames, Gérald ^b   Ferrant, Augustin ^b   Lehmann, Frédéric ^b   André, Marc ^b   Ravoet, Christophe ^b   Doyen, Chantal ^b   Spagnoli, Giulio C ^b   Bakkus, Marleen ^b   Thielemans, Kris ^b   Boon, Thierry ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION SYSTEM; HLA SYSTEM; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033567078     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Singhal S, Mehta J, Barlogie B: Advances in the treatment of multiple myeloma. Curr Opin Hematol 4:291, 1997
2. Peest D, Leo R, Bloche S, Hein R, Stannat-Kiessling S, Tschechne B, Fett W, Harms P, Hoffmann L, Bartl R: Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol 89:328, 1995 (suppl 2)
3. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996
4. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 347:800, 1996
5. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma. Long-term results of a clinical trial. Blood 89:3129, 1997
6. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma-idiotype-specific immunity from an actively immunized marrow donor. Lancet 345:1016, 1995
7. Österborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Rudén U, Lefvert AK, Holm G, Mellstedt H: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood 91:2459, 1998
8. Barratt-Boyes SM: Making the most of mucin: A novel target for tumor immunotherapy. Cancer Immunol Immunother 43:142, 1996
9. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted cytotoxic T lymphocytes against MUC1 from a multiple myeloma patient. J Immunol 152:2102, 1994
10. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K: Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 9:791, 1997
11. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643, 1991
12. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T: Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40:360, 1994
13. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K: Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 55:3478, 1995
14. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P: BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167, 1995
15. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689, 1995
16. Lethé B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T: LAGE-1, a new gene with tumor specificity. Int J Cancer 76:903, 1998
17. Chen YT, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914, 1997
18. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93:7149, 1996
19. Ikeda H, Lethé B, Lehmann F, Van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG: Cytolytic T cells expressing NK inhibitory receptor p58.2 recognize on a melanoma metastasis lacking HLA-Cw7 an antigen encoded by a gene which is preferentially expressed in tumors. Immunity 6:199, 1997
20. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG: PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102:1376, 1998
21. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, François P, Abi Aad A, Van Cangh P, Abbou CC, Chopin D, Boon T: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 64:60, 1995
22. van der Bruggen P, Bastin J, Gajewski T, Coulie P, Boël P, De Smet C, Traversari C, Townsend A, Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038, 1994
23. Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M: Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med 152:1184, 1980
24. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T: Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145, 1992
25. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli G: Identification and intracellular location of MAGE-3 gene product. Cancer Res 55:2236, 1995
26. Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaye T, Degiovanni G, Deraemaecker R, Beauduin M, Sastre X, Salamon E, Dréno B, Jäger E, Knuth A, Chevreau C, Suciu S, Lachapelle M, Pouillart P, Parmiani G, Lejeune F, Cerottini JC, Boon T, Marchand M: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375, 1995
27. Yi Q, Dabadghao S, Österborg A, Bergenbrant S, Holm G: Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells. Blood 90:1960, 1997
28. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219, 1999
29. Hallek M, Bergsagel PL, Anderson K: Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 91:3, 1998
30. Ohtsuki T, Nishitani K, Hatamochi A, Yawata Y, Namba M: Analysis of methylation in the c-MYC gene in five human myeloma cell lines. Br J Haematol 77:172, 1991
31. Durie B, Salmon S: A clinical staging system for multiple myeloma. Cancer 36:842, 1975
32. Van den Eynde B, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9:684, 1997
33. Visseren M, van der Burg S, van der Voort E, Brandt R, Schrier P, van der Bruggen P, Boon T, Melief C, Kast WM: Identification of HLA-A*0201 -restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 73:125, 1997
34. Kawashima I, Hudson S, Van Tsai, Southwood S, Takesako K, Appella E, Sette A, Celis E: The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1, 1998
35. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T: Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by Human Leukocytes Antigen-A24. Cancer Res 57:4465, 1997
36. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stocken E, Old LJ, Knuth A: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human Histocompatibility Leukocyte Antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265, 1998
37. Wang RF, Johnston S, Zeng G, Topalian S, Schwartzentruber D, Rosenberg S: A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3596, 1998